NextFin News - Regeneron Pharmaceuticals shares tumbled 12% in early Monday trading after the company announced that its high-stakes combination therapy failed to meet the primary goal of a late-stage clinical trial for advanced melanoma. The setback marks a significant blow to the company’s ambitions to challenge the dominance of established immunotherapy giants in the skin cancer market.
The Phase 3 trial evaluated the combination of fianlimab, an experimental LAG-3 inhibitor, and the approved PD-1 inhibitor Libtayo. According to a company statement released on May 18, 2026, the study failed to achieve statistical significance in improving progression-free survival (PFS) when compared head-to-head against Merck’s blockbuster drug Keytruda. While patients in the high-dose arm of the study showed a median of 11.5 months without disease progression compared to 6.4 months for those on Keytruda, the margin was insufficient to clear the rigorous statistical hurdles required for regulatory superiority.
Geoffrey Porges, an analyst at Citi, downgraded Regeneron to neutral from buy following the data release, slashing his price target from $900 to $700. Porges, who has followed the biotechnology sector for over two decades and was previously a prominent analyst at SVB Leerink, has historically maintained a balanced but often constructive view on Regeneron’s pipeline. His swift pivot reflects a growing concern that the company’s oncology strategy may face a longer and more expensive road to commercial viability than previously modeled. Porges noted that the failure "removes a key near-term catalyst" and raises questions about the competitive profile of fianlimab in an increasingly crowded field.
This downgrade and the subsequent price action currently represent a specific institutional reaction rather than a broader sell-side consensus, as several other major firms have yet to update their ratings. The market's sharp reaction, however, underscores the high expectations that had been baked into Regeneron’s valuation regarding its LAG-3 program. The company had hoped that the combination therapy would not only match but clearly outperform the current standard of care, allowing it to capture a larger slice of the multi-billion dollar melanoma market.
Despite the disappointment, Regeneron is not abandoning the program. The company confirmed it is continuing a separate Phase 3 trial comparing the same fianlimab-Libtayo combination against Bristol Myers Squibb’s Opdualag. This ongoing study remains a critical "Plan B" for the company, though the failure against Keytruda suggests that the bar for success in the first-line melanoma setting is higher than many investors anticipated. The risk remains that if the Opdualag-comparison trial also fails to show clear superiority, the commercial case for fianlimab could evaporate entirely.
The clinical failure also highlights the inherent difficulty of unseating established PD-1 inhibitors like Keytruda, which has become the foundational therapy for numerous cancers. For Regeneron, the path forward now relies heavily on its ability to prove that its combination therapy offers a distinct safety or efficacy advantage in specific patient subgroups, a task that becomes significantly harder without the momentum of a successful pivotal trial. The stock's double-digit decline reflects a recalibration of the company's growth trajectory as the "oncology pillar" of its future revenue faces its first major structural crack.
Explore more exclusive insights at nextfin.ai.
